NasdaqCM:IRDBiotechs
Opus Genetics (IRD) Trailing US$49.6m Loss Reinforces Bearish Profitability Narrative
Opus Genetics (IRD) has reported FY 2025 results with Q4 revenue of US$3.9 million, a basic EPS loss of US$0.21, and a net income loss of US$16.5 million. The trailing twelve month figures show revenue of US$14.2 million, a basic EPS loss of US$0.80, and a net income loss of US$49.6 million. Over the recent quarters in FY 2025, the company has reported revenue between US$2.9 million and US$4.4 million, while quarterly basic EPS losses have ranged from US$0.12 to US$0.25 per share. These...